Compare ING Groep NV (ING) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Revvity Inc — how do they compare? ING Groep NV trades at $35.62 (market cap $101.22B), while Revvity Inc trades at $115.25 (market cap $12.91B). The key difference: ING Groep NV is far larger — about 7.8× Revvity Inc's market cap, and ING Groep NV pays the higher dividend (3.73%). Which is the better fit depends on your goals.
| ING | RVTY | |
|---|---|---|
Market Cap | $101.22B | $12.91B |
Sector | Financials | Technology |
52-Week High | $35.92 | $117.75 |
52-Week Low | $23.66 | $82.26 |
Dividend Yield | 3.73% | 0.24% |
Enterprise Value | — | $15.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $35.24, down 1.23% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.79, and raised its full-year revenue guidance. Analyst consensus is strongly positive with 62.5% buy ratings. Recent news highlights strategic acquisitions and a dividend payment scheduled for August 2026.
The outlook for ING is favorable, supported by earnings momentum and upward guidance revisions. Key opportunities include growth in net interest income and fee-based revenue. Risks involve persistent negative operating cash flows and sensitivity to European economic conditions. The stock presents a value proposition with a P/E of 13.24, though cash flow trends warrant monitoring.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
